Nanexa launches its own product development of cancer drugs for indications with high medical needs and growing market potential.

Pressrelease

Uppsala 26th June 2018

Nanexa launches its own product development of cancer drugs for indications with high medical needs and growing market potential.

 

Nanexa’s Board of Directors has decided to start product development for a product based on Nanexa’s drug delivery platform PharmaShell®. The product opportunities are based both on clinical needs and market potential, where an active substance formulated with PharmaShell® is expected to provide significant added value over todays formulations. The decision is based on the work done with the scientific advisory board appointed at the beginning of the year and further information from specialists in each indication field.

The indications that Nanexa focuses on are two types of leukemia called MDS and AML (Myelodysplastic Syndrome and Acute Myeloid Leukemia), as well as peritoneum methastases from colon and ovary cancers (Colorectal / Ovarian Peritoneal Carcinomatosis). Treatment of these conditions is considered to be more effective using slow and controlled release of drugs, which can be enabled by PharmaShell®. In addition to better efficacy, which could lead to longer survival for patients, a PharmaShell® based product is also expected to reduce the risk of side effects and simplify the treatment routine for both the patient and the healthcare, thus providing reduced healthcare costs.

Nanexa is now starting a technical evaluation of selected active substances to begin the preclinical development of one of the projects during the autumn. The company will in parallel initiate dialogue with potential licensing partners and relevant authorities regarding the preclinical plans and designs of a first clinical study, which is planned to be conducted with a partner or in-house. Before the plans are discussed with the authorities, it is difficult to specify an exact time when a clinical study can start, but the aim is to make this happen in the next year.

 

David Westberg, CEO comments:

“During the autumn of 2017, we announced that the company intends to start a development project, which I already commented on as a strategic decision for the company. I am now very pleased with the decision on indications to focus this work on. The product project provides opportunities for both new licensing revenues and it also provides valuable information for outlicensing the PharmaShell® technology itself and its capabilities.”

 

For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: david.westberg@nanexa.se
www.nanexa.com

About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.